Diphenylcyclopropenone treatment of alopecia areata induces apoptosis of perifollicular lymphocytes

European Journal of Dermatology

Volumn 16, Issue 5, 2006, Pages 537-542

  Herbst, Verena ^a   Zöller, Margot ^b,c   Kissling, Sabine ^a   Wenzel, Elke ^a   Stutz, Nathalie ^a   Freyschmidt Paul, Pia ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY OF KARLSRUHE   (Germany)

Author keywords

Alopecia areata; Diphenycyclopropenone; Perifollicular lymphocytes

Indexed keywords

ALPHA5 INTEGRIN; CD44V ANTIGEN; DIPHENCYPRONE; HERMES ANTIGEN;

ALOPECIA AREATA; APOPTOSIS; ARTICLE; BIOPSY; CELL POPULATION; CLINICAL ARTICLE; CONTROLLED STUDY; EXTRAVASATION; HAIR GROWTH; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPHOCYTE; NICK END LABELING; PROTEIN EXPRESSION; SCALP;

ALOPECIA AREATA; ANTIGEN-PRESENTING CELLS; ANTIGENS, CD44; APOPTOSIS; CYCLOPROPANES; DERMATOLOGIC AGENTS; FAS LIGAND PROTEIN; HAIR FOLLICLE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOCYTES; SCALP; T-LYMPHOCYTES;

EID: 33845271939     PISSN: 11671122     EISSN: None     Source Type: Journal    
DOI: 10.1684/ejd.2006.0033     Document Type: Article

References (25)

1. McElwee KJ, Tobin DJ, Bystryn JC, King Jr. LE, Sundberg JP. Alopecia areata: an autoimmune disease? Exp Dermatol 1999; 8: 371-9.
2. Perret C, Wiesner-Menzel L, Happle R. Immunohistochemical analysis of T-cell subsets in the peribulbar and intrabulbar infiltrates of alopecia areata. Acta Derm Venereol 1984; 64: 26-30.
3. McElwee KJ, Spiers EM, Oliver RF. In vivo depletion of CD8+ T cells restores hair growth in the DEBR model for alopecia areata. Br J Dermatol 1996; 135: 211-7.
4. McElwee KJ, Spiers EM, Oliver RF. Partial restoration of hair growth in the DEBR model for alopecia areata after in vivo depletion of CD4+ T cells. Br J Dermatol 1999; 140: 432-7.
5. Gilhar A, Shalaginov R, Assy B, Serafimovich S, Kalish RS. Alopecia areata is a T-lymphocyte mediated autoimmune disease: lesional human T-lymphocytes transfer alopecia areata to human skin grafts on SCID mice. J Invest Dermatol Symp Proc 1999; 4: 207-10.
6. McElwee KJ, Freyschmidt-Paul P, Hoffmann R, Kissling S, Hummel S, Vitacolonna M, Zöller M. Transfer of CD8(+) cells induces localized hair loss whereas CD4(+)/CD25(-) cells promote systemic alopecia areata and CD4(+)/CD25(+) cells blockade disease onset in the C3H/HeJ mouse model. J Invest Dermatol 2005; 124: 947-57.
7. Zöller M, McElwee KJ, Vitacolonna M, Hoffmann R. Apoptosis resistance in peripheral blood lymphocytes of alopecia areata patients. J Autoimmun 2004; 23: 241-56.
8. Freyschmidt-Paul P, Hoffmann R, Levine E, Sundberg JP, Happle R-McElwee KJ. Current and potential agents for the treatment of alopecia areata. Curr Pharm Des 2001; 7: 213-30.
9. Freyschmidt-Paul P, Sundberg JP, Happle R, McElwee KJ, Metz S, Boggess D, Hoffmann R. Successful treatment of alopecia areata-like hair loss with the contact sensitizer squaric acid dibutylester (SADBE) in C3H/HeJ mice. J Invest Dermatol 1999; 113: 61-8.
10. Happle R, Echternacht K. Induction of hair growth in alopecia areata with D.N.C.B. Lancet 1977; 2: 1002-3.
11. Happle R, Kalveram KJ, Büchner U, Echternacht-Happle K, Göggelmann W, Summer KH. Contact allergy as a therapeutic tool for alopecia areata: application of squaric acid dibutylester. Dermatologica 1980; 161: 289-97.
12. Happle R, Klein HM, Macher E. Topical immunotherapy changes the composition of the peribulbar infiltrate in alopecia areata. Arch Dermatol Res 1986; 278: 214-8.
13. Hoffmann R, Wenzel E, Huth A, van der Steen P, Schäufele M, Henninger HP, Happle R. Cytokine mRNA levels in alopecia areata before and after treatment with the contact allergen diphenylcyclopropenone. J Invest Dermatol 1994; 103: 530-3.
14. Gupta P, Freyschmidt-Paul P, Hummel S, Vitacolonna M, Hildebrand D, Kissling S, Marhaba R, Zöller M. The impact of a chronic DTH reaction on leukocyte migration in alopecia areata. J Invest Dermatol 2006; 126: 1559-73.
15. Hoffmann R, Happle R. Topical immunotherapy in alopecia areata: what, how, and why? Dermatol Clin 1996; 14: 739-44.
16. Szczepanik M, Akahira-Azuma M, Bryniarski K, Tsuji RF, Kawikova I, Ptak W, Kiener C, Campos RA, Askenase PW. B-1 B cells mediate required early T cell recruitment to elicit protein-induced delayed-type hypersensitivity. J Immunol 2003; 171: 6225-35.
17. Lynch DH, Ramsdell F, Alderson MR. Fas and FasL in the homeostatic regulation of immune responses. Immunol Today 1995; 16: 569-74.
18. Alderson MR, Tough TW, Davis-Smith T, Braddy S, Falk B, Schooley KA, Goodwin RG, Smith CA, Ramsdell R, Lynch DH. Fas Ligand mediates activation-induced cells death in human T lymphocytes. J Exp Med 1995; 181: 71-7.
19. Van Parijs L, Abbas AK. Homeostasis and self-tolerance in the immune system: turning lymphocytes off. Science 1998; 280: 243-8.
20. + T cells in the immune response to the contact senitizer trinitrophenyl. J Immunol 2004; 173: 3178-85.
21. Wittig B, Schwarzler C, Fohr N, Gunthert U, Zöller M. Curative treatment of an experimentally induced colitis by a CD44 variant V7-specific antibody. J Immunol 1998; 161: 1069-73.
22. Marhaba R, Freyschmidt-Paul P, Zöller M. In vivo CD44-CD49d complex formation in autoimmune disease and its consequences in T cell activation and apoptosis resistance. Submitted.
23. Rösel M, Seiter S, Zöller M. CD44v10 expression in the mouse and functional activity in delayed type hypersensitivity. J Cell Physiol 1997; 171: 305-17.
24. Freyschmidt-Paul P, Seiter S, Zöller M, König A, Ziegler A, Sundberg JP, Happle R, Hoffmann R. Treatment with an anti-CD44v10-specific antibody inhibits the onset of alopecia areata in C3H/HeJ mice. J Invest Dermatol 2000; 115: 653-7.
25. Zöller M, Gupta P, Vitacolonna M, Hummel S, Freyschmidt-Paul P. The impact of a CD44 blockade on leukocyte migration in a skin-associated autoimmune disease treated by a contact allergen. Submitted.